Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis

OBJECTIVE: Guselkumab, a human monoclonal antibody specific to interleukin‐23p19, demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER‐2 trial in biologic‐naive patients with psoriatic arthritis (PsA). Here we report 1‐year DISCOVER‐2 findings. METHODS: Adults wi...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B., Rahman, Proton, Gottlieb, Alice B., Hsia, Elizabeth C., Kollmeier, Alexa P., Chakravarty, Soumya D., Xu, Xie L., Subramanian, Ramanand A., Agarwal, Prasheen, Sheng, Shihong, Jiang, Yusang, Zhou, Bei, Zhuang, Yanli, van der Heijde, Désirée, Mease, Philip J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291746/
https://www.ncbi.nlm.nih.gov/pubmed/33043600
http://dx.doi.org/10.1002/art.41553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291746/
https://www.ncbi.nlm.nih.gov/pubmed/33043600
http://dx.doi.org/10.1002/art.41553

Ejemplares similares